LivaNova (LIVN) Cash from Financing Activities (2015 - 2026)

LivaNova (LIVN) reported Cash from Financing Activities of -$94.2 million for Q1 2026, down 2031.76% on a YoY basis from $4.9 million in Q1 2025, and down 49.87% sequentially from -$62.9 million in Q4 2025.

LivaNova (LIVN) Cash from Financing Activities (2015 - 2026) Analysis & Trends

LivaNova (LIVN) has 12 years of Cash from Financing Activities data on file, last reported at -$94.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities fell 2031.76% year-over-year to -$94.2 million; the trailing twelve-month figure through Mar 2026 stood at -$375.5 million (down 1531.33% YoY), and the FY2025 full-year result was -$285.7 million, down 1639.86% from the prior year.
  • Cash from Financing Activities eased to -$94.2 million in Q1 2026, from -$62.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $214.9 million in Q1 2022 to a low of -$209.0 million in Q2 2025.
  • A 5-year average of -$3.5 million and a median of -$4.4 million in 2025 frame the typical range for Cash from Financing Activities.
  • Across the five-year window, Cash from Financing Activities surged 2680.18% in 2022 and plunged 2031.76% in 2026, its largest moves.
  • Tracing LIVN's Cash from Financing Activities over 5 years: stood at -$1.7 million in 2022, then tumbled by 202.84% to -$5.0 million in 2023, then jumped by 31.37% to -$3.4 million in 2024, then slumped by 1725.9% to -$62.9 million in 2025, then sank by 49.87% to -$94.2 million in 2026.
  • Business Quant data shows LIVN's Cash from Financing Activities at -$94.2 million in Q1 2026, -$62.9 million in Q4 2025, and -$9.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 17.31 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -1.51 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn -888.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -260.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -451.20 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -25.00 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -26.93 Mn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 21.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 LivaNova 4.30 Bn 3.76 Bn 243.75 Mn -94.25 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -94.25 Mn
Mar 31, 2026 -94.25 Mn
Dec 31, 2025 -62.88 Mn
Dec 31, 2025 -62.88 Mn
Sep 30, 2025 -9.37 Mn
Sep 30, 2025 -9.37 Mn
Jun 30, 2025 -208.98 Mn
Jun 30, 2025 -208.98 Mn
Mar 31, 2025 -4.42 Mn
Mar 31, 2025 -4.42 Mn
Dec 31, 2024 -3.44 Mn
Dec 31, 2024 -3.44 Mn
Sep 30, 2024 -3.28 Mn
Sep 30, 2024 -3.28 Mn
Jun 30, 2024 -11.87 Mn
Jun 30, 2024 -11.87 Mn
Mar 31, 2024 37.15 Mn
Mar 31, 2024 37.15 Mn
Dec 31, 2023 -5.02 Mn
Dec 31, 2023 -5.02 Mn